Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on February 9, 2023, at 10:10 a.m. ET. The event will be streamed live and accessible on their website under the Events section. An archived replay will be available for 30 days post-presentation.
Relay Therapeutics is a clinical-stage precision medicine company focused on enhancing drug discovery through its innovative Dynamo™ platform, targeting oncology and genetic diseases. This cutting-edge approach combines computational and experimental technologies to develop impactful therapies for patients.
- None.
- None.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 9, 2023 at 10:10 a.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When is Relay Therapeutics participating in the Guggenheim Healthcare Talks | Oncology Day?
How can I watch the Relay Therapeutics fireside chat?
Will there be a replay available for the Relay Therapeutics fireside chat?
What is the focus of Relay Therapeutics in drug discovery?
What is the ticker symbol for Relay Therapeutics?
